Enterprise Therapeutics closes £4m funding round
Portfolio company Enterprise Therapeutics, a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases, has closed a £4 million funding round, led by Innovations and Epidarex Capital.
The funds will be used to accelerate Enterprise’s three drug discovery programmes. The company aims to treat chronic respiratory diseases, such as Cystic Fibrosis (CF) and Chronic Obstructive Pulmonary Disease (COPD), using novel muco-regulatory therapies. The potential new drugs would target mechanisms that increase the clearance of mucus or reduce levels of mucus production in order to alleviate the symptoms and complications associated with respiratory disease.
Dr Rob Woodman, Investor Director, Imperial Innovations commented: “Enterprise Therapeutics has made significant progress in the 18 months since Imperial Innovations first invested. We believe that the Company has the potential to become a leading player in respiratory disease.”
About Enterprise Therapeutics
Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. The company is backed by Epidarex Capital and Imperial Innovations and based in the UK with offices in Cambridge and at the University of Sussex. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. Enterprise Therapeutics’ scientific strategy is aimed at discovering new disease modifying therapies that target the underlying mechanisms of mucus congestion, which will reduce the frequency of lung infections and improve patient quality of life. These novel muco-regulatory therapies are being achieved through targeting TMEM16A and ENaC to increase the hydration and clearance of mucus. Enterprise has also identified novel targets and compounds that reduce mucus production, an approach that compliments mucus hydration therapies. Its management team has significant expertise in drug discovery, drug development, respiratory biology and ion channel pharmacology. The company benefits from a close working relationship with the School of Life Sciences at the University of Sussex.
Source: Imperial Innovations